
Quarterly report 2025-Q3
added 11-19-2025
ProPhase Labs Financial Statements 2011-2025 | PRPH
Annual Financial Statements ProPhase Labs
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
131 M | 109 M | 117 M | 22.7 M | 34.2 M | 37.7 M | 33.6 M | 20 M | 26.7 M | 31.8 M | 23.9 M | 17.8 M |
Shares |
15.8 M | 15.2 M | 11.6 M | 11.6 M | 11.4 M | 15.6 M | 17.1 M | 16.4 M | 16.8 M | 15.8 M | 14.8 M | 14.8 M |
Historical Prices |
8.24 | 7.17 | 8.75 | 1.66 | 2.46 | 1.25 | 1.15 | 0.865 | 0.842 | 0.929 | 0.785 | 0.664 |
Net Income |
18.5 M | 6.27 M | -2.12 M | -3.15 M | -1.74 M | 41.8 M | -2.87 M | -3.6 M | -7.83 M | 405 K | -1.09 M | -2.71 M |
Revenue |
123 M | 79 M | 14.5 M | 9.88 M | 13.1 M | 9.87 M | 21 M | 20.6 M | 22.1 M | 25 M | 22.4 M | 17.5 M |
Cost of Revenue |
52 M | 37.1 M | 9.91 M | 7.26 M | 8.34 M | 7.92 M | 3.21 M | 1.69 M | 7.89 M | 8.36 M | 8.15 M | 6.17 M |
Gross Profit |
70.7 M | 42 M | 4.61 M | 2.62 M | 4.78 M | 1.95 M | 10.1 M | 12.2 M | 14.2 M | 16.7 M | 14.3 M | 11.3 M |
Operating Income |
23.6 M | 9.8 M | -2.08 M | -3.24 M | -1.63 M | -3.99 M | -2.66 M | -3.58 M | -7.83 M | 416 K | -1.1 M | -2.74 M |
Interest Expense |
764 K | 1.15 M | 295 K | - | 167 K | 54 K | 213 K | 18 K | 10 K | 13 K | - | - |
EBITDA |
28.3 M | 13 M | -1.64 M | -2.84 M | -1.25 M | -3.65 M | -2.23 M | -3.22 M | -3.97 M | 659 K | -1.87 M | -2.38 M |
Operating Expenses |
47.1 M | 32.2 M | 8.59 M | 5.85 M | 6.42 M | 5.94 M | 12.7 M | 15.8 M | 18.4 M | 16.3 M | 16.4 M | 14 M |
General and Administrative Expenses |
34.4 M | 22.5 M | 6.67 M | 4.48 M | 4.91 M | 4.81 M | 5.06 M | 6.99 M | 8.14 M | 5.89 M | 6.13 M | 5.03 M |
All numbers in USD currency
Quarterly Income Statement ProPhase Labs
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
41.5 M | 41.5 M | 35.2 M | 29.9 M | 19.1 M | 18.9 M | 17.2 M | 18 M | 17.2 M | 16.8 M | 16.7 K | 16.2 M | 15.9 M | 15.6 K | 15.5 K | 15.5 M | 15.4 K | 15.2 K | 14.6 K | 11.6 M | 11.6 M | 11.6 K | 11.6 M | - | 11.6 M | 11.6 K | 11.6 M | - | 11.5 K | 11.3 M | 11.1 M | - | 16 K | 16.9 M | 17.1 M | - | 17.1 M | 17.1 K | 17.1 M | - | 16.6 K | 16 K | 15.9 K | - | 18.2 K | 16.9 K | 16.5 M | - | 15.9 M | 15.8 K | 15.8 M | - | 14.8 M | 14.8 M | 14.8 M | - | 15.1 K | 15 K | - |
Net Income |
-6.84 M | -4.47 M | 3.97 M | - | -6.59 M | -6.15 M | -6.26 M | - | -5.14 M | -3.44 M | 550 K | - | 968 K | 7.45 M | 12.5 M | - | -3.98 M | -1.4 M | 1.06 M | - | -408 K | 70 K | -809 K | - | -428 K | -1.24 M | -1.01 M | - | -1.06 M | -259 K | 43 K | - | -777 K | -2.3 M | 43.9 M | - | 167 K | -1.13 M | -1.34 M | -1.26 M | 602 K | -1.57 M | -1.38 M | -676 K | -3.22 M | -3.14 M | -804 K | 597 K | 1.24 M | -1.72 M | 290 K | 453 K | 1.07 M | -1.93 M | -688 K | -1.83 M | 1.11 M | -976 K | -1.01 M |
Revenue |
883 K | 1.25 M | 1.43 M | - | 1.42 M | 1.5 M | 2.36 M | - | 8.36 M | 13.2 M | 19.3 M | - | 24.2 M | 29.1 M | 47.5 M | - | 9.5 M | 9.1 M | 15.3 M | - | 3.84 M | 3.62 M | 1.89 M | - | 2.77 M | 1.65 M | 2.32 M | - | 2.44 M | 3.19 M | 3.41 M | - | 3.04 M | 1.9 M | 9.87 M | - | 1.4 M | 1.02 M | 1.02 M | 8.16 M | 4.39 M | 2.19 M | 5.86 M | 8.97 M | 5.13 M | 1.8 M | 6.17 M | 9.6 M | 5.95 M | 1.94 M | 7.54 M | 9.08 M | 5.42 M | 1.89 M | 6.02 M | 7.46 M | 5.08 M | 1.74 M | 3.17 M |
Cost of Revenue |
1.01 M | 513 K | 905 K | - | 1.2 M | 1.66 M | 2.42 M | - | 6.04 M | 6.77 M | 8.78 M | - | 12.2 M | 10.4 M | 18.9 M | - | 5.5 M | 4.68 M | 6.34 M | - | 2.8 M | 2.34 M | 1.47 M | - | 1.93 M | 1.39 M | 1.8 M | - | 1.68 M | 1.93 M | 1.98 M | - | 2.61 M | 1.76 M | 686 K | - | 1.2 M | 993 K | 731 K | - | 1.67 M | 1.18 M | 2.2 M | - | 1.62 M | 1 M | 2.19 M | - | 2.13 M | 1.01 M | 2.2 M | - | 2.02 M | 1.07 M | 1.68 M | - | 1.49 M | 848 K | 1.17 M |
Gross Profit |
-123 K | 734 K | 526 K | - | 215 K | -155 K | -60 K | - | 2.33 M | 6.45 M | 10.5 M | - | 12 M | 18.7 M | 28.7 M | - | 3.98 M | 4.47 M | 8.93 M | - | 1.04 M | 1.28 M | 415 K | - | 834 K | 261 K | 520 K | - | 756 K | 1.26 M | 1.42 M | - | 432 K | 140 K | 85 K | - | 197 K | 28 K | 285 K | 4.79 M | 2.72 M | 1.01 M | 3.66 M | 5.9 M | 3.51 M | 792 K | 3.98 M | 6.59 M | 3.82 M | 928 K | 5.34 M | 5.69 M | 3.4 M | 825 K | 4.34 M | 4.8 M | 3.6 M | 896 K | 1.99 M |
Operating Income |
-4.76 M | -3.89 M | -3.66 M | - | -6.48 M | -7.23 M | -7.63 M | - | -6.48 M | -4.66 M | 875 K | - | 1.95 M | 10.6 M | 16.1 M | - | -3.65 M | -1.45 M | 1.22 M | - | -567 K | 59 K | -812 K | - | -461 K | -1.27 M | -1.04 M | - | -912 K | -264 K | -53 K | - | -902 K | -886 K | -745 K | - | -786 K | -1.32 M | -1.31 M | - | 603 K | -1.57 M | -1.38 M | - | -3.22 M | -3.14 M | -802 K | - | 1.24 M | -1.72 M | 293 K | - | 1.07 M | -1.93 M | -690 K | - | 1.11 M | -983 K | -1.02 M |
Interest Expense |
- | - | -45 K | - | - | 30 K | -18 K | - | -33 K | 8 K | 215 K | - | 201 K | 201 K | 233 K | - | 296 K | 323 K | 251 K | - | 41 K | - | - | - | - | - | - | - | 15 K | 4 K | 96 K | - | 125 K | 151 K | 54 K | - | 53 K | 53 K | 52 K | - | 1 K | 1 K | 1 K | - | 1 K | 1 K | 2 K | - | 3 K | 2 K | 3 K | - | - | - | - | - | - | - | - |
EBITDA |
-4.07 M | -2.88 M | -2.18 M | - | -4.95 M | -5.7 M | -6.03 M | - | -3.91 M | -4.14 M | 2.17 M | - | 2.97 M | 11.8 M | 17.4 M | - | -1.6 M | -332 K | 1.76 M | - | -314 K | 226 K | -730 K | - | -159 K | -1.07 M | -943 K | - | -625 K | -74 K | 42 K | - | -377 K | -467 K | -422 K | - | -469 K | -1.11 M | -1.2 M | - | 863 K | -1.4 M | -1.3 M | - | -3.01 M | -3 M | -738 K | - | 1.42 M | -1.6 M | 355 K | - | 1.26 M | -1.81 M | -632 K | - | 1.4 M | -789 K | -928 K |
Operating Expenses |
4.64 M | 4.63 M | 4.19 M | - | 6.7 M | 7.07 M | 7.57 M | - | 8.8 M | 11.1 M | 9.64 M | - | 10 M | 8.13 M | 12.5 M | - | 7.62 M | 5.92 M | 7.71 M | - | 1.61 M | 1.22 M | 1.23 M | - | 1.3 M | 1.53 M | 1.56 M | - | 1.67 M | 1.52 M | 1.48 M | - | 1.33 M | 1.75 M | 1.23 M | - | 930 K | 1.3 M | 1.54 M | - | 2.12 M | 2.57 M | 5.04 M | - | 6.72 M | 3.93 M | 4.78 M | - | 2.58 M | 2.65 M | 5.05 M | - | 2.33 M | 2.76 M | 5.03 M | - | 2.49 M | 1.88 M | 3.02 M |
General and Administrative Expenses |
4.64 M | 4.62 M | 4.09 M | - | 6.57 M | 6.93 M | 7.3 M | - | 8.24 M | 9.94 M | 8.3 M | - | 7.51 M | 6.31 M | 7.82 M | - | 5.94 M | 4.99 M | 3.78 M | - | 1.55 M | 1.16 M | 1.17 M | - | 936 K | 1.09 M | 1.2 M | - | 1.13 M | 1.2 M | 1.22 M | - | 1.12 M | 1.31 M | 1.08 M | - | 734 K | 943 K | 1.2 M | - | 1.22 M | 1.59 M | 2.02 M | - | 1.92 M | 2.8 M | 1.51 M | - | 1.31 M | 1.72 M | 1.5 M | - | 1.13 M | 1.41 M | 1.49 M | - | 1.13 M | 1.04 M | 1.24 M |
All numbers in USD currency
Main types of financial statements ProPhase Labs PRPHFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting ProPhase Labs plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Drug manufacturers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | ||
|
Assertio Holdings
ASRT
|
$ 0.73 | -3.6 % | $ 51.9 M | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
$ 1.7 | -2.59 % | $ 183 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | ||
|
Cronos Group
CRON
|
$ 3.07 | -6.25 % | $ 1.6 B | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | ||
|
Aurora Cannabis
ACB
|
$ 5.11 | -5.46 % | $ 86.3 M | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | ||
|
Emergent BioSolutions
EBS
|
$ 12.37 | 8.32 % | $ 633 M | ||
|
Evoke Pharma
EVOK
|
$ 10.96 | 0.09 % | $ 36.6 M | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.43 | 0.3 % | $ 2.04 B | ||
|
Evolus
EOLS
|
$ 7.18 | 1.99 % | $ 445 M | ||
|
Harrow Health
HROW
|
$ 46.29 | -1.64 % | $ 1.51 B | ||
|
China Pharma Holdings
CPHI
|
$ 1.53 | -1.92 % | $ 26.7 M | ||
|
Bausch Health Companies
BHC
|
$ 6.9 | -0.36 % | $ 2.52 B | ||
|
Organogenesis Holdings
ORGO
|
$ 4.78 | -0.83 % | $ 629 M | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | ||
|
Pacira BioSciences
PCRX
|
$ 26.61 | 1.22 % | $ 1.23 B | ||
|
OrganiGram Holdings
OGI
|
$ 1.8 | -6.19 % | $ 402 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 3.11 | 22.92 % | $ 43.7 M | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | ||
|
Rockwell Medical
RMTI
|
$ 0.88 | -5.3 % | $ 20.5 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 3.55 | -1.11 % | $ 4.41 M | ||
|
Solid Biosciences
SLDB
|
$ 5.75 | -2.04 % | $ 235 M | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
$ 4.34 | 6.91 % | $ 131 M | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | ||
|
Perrigo Company plc
PRGO
|
$ 12.77 | -2.78 % | $ 1.75 B | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | ||
|
Sundial Growers
SNDL
|
$ 1.99 | -9.95 % | $ 3.37 M | ||
|
Veru
VERU
|
$ 2.4 | -0.83 % | $ 324 M | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | ||
|
cbdMD
YCBD
|
$ 1.19 | -0.83 % | $ 5.13 M | ||
|
SCYNEXIS
SCYX
|
$ 0.64 | -0.91 % | $ 30.6 M | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | ||
|
Tilray
TLRY
|
$ 11.01 | -9.4 % | $ 6.8 B | ||
|
TherapeuticsMD
TXMD
|
$ 1.7 | -2.86 % | $ 17.7 M | ||
|
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | ||
|
Viatris
VTRS
|
$ 11.68 | 0.29 % | $ 14.2 B |